Meeting
2019 ASCO Annual Meeting
A TITE-CRM phase I/II study of disulfiram and copper with concurrent radiation therapy and temozolomide for newly diagnosed glioblastoma.
Authors
Jiayi Huang
Washington University School of Medicine in St. Louis, St. Louis, MO
Jiayi Huang , Todd DeWees , Jian Li Campian , Milan G Chheda , George Ansstas , Christina Tsien , Gregory J. Zipfel , Gavin P. Dunn , Jospeh E Ippolito , J. Gregory Cairncross , Jacob C. Easaw , Josh Rubin , Albert H Kim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT02715609
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2033)
DOI
10.1200/JCO.2019.37.15_suppl.2033
Abstract #
2033
Poster Bd #
222
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase IB trial of carboxyamidotriazole orotate (CTO) and radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ) in newly diagnosed glioblastoma (GBM).
First Author: Antonio Marcilio Padula Omuro
Poster
2015 ASCO Annual Meeting
Phase IB trial of carboxyamidotriazole orotate (CTO) and radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ) in newly diagnosed glioblastoma (GBM).
First Author: Alissa A. Thomas
Poster
2018 ASCO Annual Meeting
Phase I study of afatinib and radiotherapy (RT) with or without temozolomide (TMZ) in newly diagnosed glioblastoma (GB).
First Author: Frank Saran
Poster
2018 ASCO Annual Meeting
Phase I clinical trials evaluating olaparib in combination with radiotherapy (RT) and/or temozolomide (TMZ) in glioblastoma patients: Results of OPARATIC and PARADIGM phase I and early results of PARADIGM-2.
First Author: Anthony J. Chalmers